Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal fenofibrate
- Development stage
- Phase 1
- Lead developer
- Neopharm
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
LEP-F1 is a liposomal formulation of fenofibrate, a small molecule peroxisome proliferator-activated receptor alpha (PPAR-alpha) agonist. Developed by NeoPharm, the drug was designed to leverage the anti-angiogenic and pro-apoptotic properties of fenofibrate for the treatment of solid tumors. Fenofibrate is traditionally indicated for hypertriglyceridemia, but research suggested it could inhibit tumor growth by modulating lipid metabolism and downregulating vascular endothelial growth factor (VEGF) expression. The liposomal delivery system was intended to improve the pharmacokinetic profile and tumor-specific accumulation of the hydrophobic fenofibrate molecule. Development appears to have stalled in the early clinical or preclinical stages following corporate restructuring at NeoPharm.
- Other names
- LEP-F1LEP-F-1LEP-F 1liposomal fenofibrate
02
Targets
PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on liposomal fenofibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal fenofibrate.